PubRank

The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (ICE)

Clinical Trial ID NCT01331525

PubWeight™ 19.92‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01331525

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011 1.97
2 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
3 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
4 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
5 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
6 Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013 1.05
7 Small cell lung cancer: therapies and targets. Semin Oncol 2013 1.02
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
10 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
11 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
12 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
13 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
14 Novel therapies in small cell lung cancer. Transl Lung Cancer Res 2015 0.84
15 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.82
16 The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist 2016 0.78
17 Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open 2016 0.77
18 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
19 Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol 2016 0.75
Next 100